Quantum Genesis AI Corp.

What they do

The company engineers enzymes to improve activity, selectivity, and specificity using quantum mechanics, molecular modelling, and computational protein design. Its first product is an enzyme for use in the pharmaceutical API production of ibuprofen, aimed at generic drug manufacturers. It also intends to expand into fragrances and flavors, sustainable materials, plastic degradation, and carbon capture. The intellectual property stems from an Asset Purchase Agreement dated February 21, 2023, including a pending U.S. patent application for modified polypeptides for enzymatic ibuprofen synthesis.

Revenue drivers

• Enzyme for ibuprofen API production — The only identified product, targeted at generic pharmaceutical companies; no revenue has been generated and no manufacturing or distribution partners are yet in place.
• Fragrances and flavors enzymes — Stated future expansion market; no products, partners, or revenue currently associated with this segment.
• Climate-focused enzymes — Stated future expansion into sustainable materials, plastic degradation, and carbon capture; no products, partners, or revenue currently associated with these applications.

Recent performance

The company earned no revenues for the three and nine months ended April 30, 2026 or 2025. For the three months ended April 30, 2026, operating expenses fell to $19,083 from $60,453 a year earlier, and net loss narrowed to $24,912 from $65,763. For the nine months ended April 30, 2026, operating expenses were $59,661 versus $145,921, but net loss ballooned to $4,404,437 from $161,092 due to a $4,344,776 other expense from a loss on settlement of debt. As of April 30, 2026, total assets were $59, total liabilities were $443,313, and shareholders' equity was negative $443,254.

Strategy

The company is focused on completing development of its engineered enzyme for ibuprofen API production and identifying third-party manufacturers and distributors to produce and sell the product at scale. It plans to expand its enzyme platform into fragrances and flavors and climate-focused applications such as sustainable materials, plastic degradation, and carbon capture. Management expects operating expenses to increase as operating activity grows and is seeking financing through securities sales or private investment. The company has no firm financing agreements and has stated it will likely curtail development plans if unable to raise funds.

Risks

• Going concern — During the nine months ended April 30, 2026, the company incurred a net loss of $4,404,437, had an accumulated deficit of $10,041,004, and used $62,953 in cash operations, raising substantial doubt about its ability to continue as a going concern.
• No revenue or commercial partners — The company has never generated revenue and has not yet secured manufacturers or distributors for its only product, an enzyme for ibuprofen API production.
• IP ownership — The U.S. patent application for the ibuprofen enzyme was filed in the name of the CEO individually, and the company has entered an Assignment Agreement to formalize the transfer, effective November 2, 2023.
• Key person dependence — The company depends entirely on the continued services of its sole management team member, Mr. Kulkarni, and the loss of his services could disrupt operations and growth.

Outlook

Management states that operating expenses are expected to increase in future years due to costs associated with increased operating activity. The company is entirely dependent on raising funding through securities sales or outside sources and currently has no firm financing agreements. Without additional funds, management may be required to curtail development plans or suspend operations. No revenue guidance or specific commercialization timelines are provided in the excerpts.